Clinical Trials Logo
  1. Home
  2. Cardiovascular Diseases
  3. NCT05856487
  4. Details
NCT05856487 Clinical Trial

To Evaluate the Safety and Efficacy of NVP-2203 Tablet in Patients

Cardiovascular Diseases Clinical Trial

Official title:
A Multicenter, Randomized, Double-blind, Parallel-group, Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of NVP-2203 Tablet in Patients

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05856487
Other study ID # NVP-2203_P3
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date June 30, 2023
Est. completion date October 31, 2024

Study information
Verified date May 2023
Source NVP Healthcare
Contact HR Lim
Phone +82-31-547-9781
Email hrlim@nvp-healthcare.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety NVP-2203 in patients

Description:

This study is a multicenter, randomized, double-blind, parallel-group, phase 3 clinical trial to evaluate efficacy and safety of NVP-2203 in patients

Recruitment information / eligibility
Status Recruiting
Enrollment 228
Est. completion date October 31, 2024
Est. primary completion date May 31, 2024
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: - Adults = 19 years of age - Primary hypercholesterolemia - Subjects who have ability to comprehend the contents of study and before participating in trial and have willingness to sign of informed consent in writing Exclusion Criteria: - The subject not meet the specified LDL-C level - Patients who were diagnosed with a malignant tumor within five years before Visit - Inadequate subject for the clinical trial by the investigator's decision

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• NVP-2203
Take it once daily for 8 weeks orally.
• NVP-2203-R1
Take it once daily for 8 weeks orally.
• NVP-2203-R2
Take it once daily for 8 weeks orally.
• NVP-2203-R3
Take it once daily for 8 weeks orally.
• NVP-2203 Placebo
Take it once daily for 8 weeks orally.
• NVP-2203-R1 Placebo
Take it once daily for 8 weeks orally.
• NVP-2203-R2 Placebo
Take it once daily for 8 weeks orally.
• NVP-2203-R3 Placebo
Take it once daily for 8 weeks orally.

Locations
Country Name City State
Korea, Republic of NVPhealthcare Suwon-si Gyeonggi-do

Sponsors (1)
Lead Sponsor Collaborator
NVP Healthcare

Country where clinical trial is conducted

Korea, Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary % change in LDL-C level from baseline change in LDL-C level Week 8
Secondary % change in lipid panel from baseline change in lipid panel Week 4, 8
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)